Tissue Repair Ltd (TRP) AI Stock Analysis

• Market Cap: AU$9.67M
• Dividend Yield: N/A
• Average Volume (3M): 93.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.56
• Revenue Growth: 178.06%
• EPS Growth: -2.49%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 60,464,844
• 10 Day Avg. Volume: 171,402
• 30 Day Avg. Volume: 93,720
• PEG Ratio: -1.06
• Price to Book (P/B): 0.80
• Price to Sales (P/S): 4.25
• P/FCF Ratio: -2.71
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: AU$0.18 ▼(-53.68% Downside)
• Action: Reiterated Date: 01/31/26
• Date: Action: Reiterated 01/31/26

The score is held back primarily by sustained losses and ongoing negative free cash flow despite accelerating revenue and a debt-free balance sheet. Technicals add further pressure with a strong downtrend (below all major DMAs and negative MACD), while extremely oversold readings provide only modest offset. Valuation is difficult to support because the company is loss-making and has no dividend yield data.

Positive Factors

Revenue acceleration & high gross margins

The sharp revenue rise to A$2.63m in 2025 combined with very high gross margins indicates improving unit economics and early commercial traction. Over a medium-term horizon this trend supports stronger organic funding for programs, makes partnerships more attainable, and reduces reliance on purely dilutive capital if sustained.

Zero debt / conservative leverage

A debt-free balance sheet materially lowers financial risk and interest obligations, giving management flexibility to prioritize clinical development choices. For a clinical-stage biotech, lack of leverage preserves runway options, simplifies capital structure decisions, and reduces refinancing pressure over the coming months.

Proprietary tissue repair platform & clinical-stage lead

Owning a platform technology and a clinical-stage lead program provides a durable R&D asset and potential for multiple downstream candidates. Platform-based IP can attract partnerships, licensing deals, and milestone-driven non-dilutive funding that materially strengthens long-term growth prospects if clinical milestones progress.

Negative Factors

Persistent negative free cash flow and cash burn

Sustained negative operating and free cash flow reflects material cash burn tied to development activity. Over 2–6 months this creates a continuing need for external financing, raising dilution risk, constraining strategic flexibility, and potentially forcing slower program progression absent new funding sources.

Deep net losses and negative margins

Very large negative margins and persistent operating losses indicate the company is far from breakeven. Structurally, this limits internal capacity to fund growth or commercialization, increases dependence on capital markets or partners, and elevates execution risk for translating R&D into sustainable revenue.

Material equity decline / value erosion

A marked fall in shareholders' equity over recent years signals cumulative losses and a shrinking balance-sheet buffer. This erosion reduces resilience to operational setbacks, limits ability to use equity for strategic transactions, and raises the likelihood of future dilutive raises to sustain clinical programs.

Tissue Repair Ltd Business Overview & Revenue Model

Company Description

Tissue Repair Ltd, a clinical stage biopharmaceutical company, developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. It is developing TR-987 and other dressing/matrices, including Glucoprime technology for the treatment of chronic wounds, burns, and other complex wounds; and TR Pro+ for aftercare of minimally invasive cosmetic procedures, as well as other products for veterinary, new bandage, scaffold products, and other therapeutic indications. The company was incorporated in 2012 and is headquartered in Sydney, Australia.

How the Company Makes Money

Tissue Repair Ltd generates revenue primarily through the sale of its proprietary therapeutic products to hospitals, clinics, and healthcare providers. These products are marketed and distributed both directly and through strategic partnerships with pharmaceutical companies and medical device distributors. TRP also earns income through licensing agreements, where it grants rights to other companies to use its patented technologies in exchange for royalties or upfront payments. Additionally, TRP may receive funding through research grants and collaborations with academic institutions or government agencies, which support the development of new therapies and expand its product pipeline.

Tissue Repair Ltd Financial Statement Overview

Summary

Revenue accelerated sharply in 2025 (A$2.63m vs A$0.15m in 2024) with very high recent gross margins and no debt, but the company remains deeply unprofitable with persistent operating losses, negative free cash flow (2025 FCF about -A$4.1m), and declining equity—keeping funding/dilution risk elevated.

Income Statement

Revenue has accelerated sharply into 2025 (A$2.63m vs A$0.15m in 2024), and gross margin is very high in the latest two years. However, profitability remains weak: EBIT and net income are deeply negative across the period, with 2025 net margin around -161% and persistent operating losses indicating the business is still in heavy investment mode with limited earnings visibility.

Balance Sheet

The balance sheet is conservatively levered with zero debt from 2022–2025 and a 0.0 debt-to-equity ratio in the most recent years, which meaningfully reduces financial risk. The key weakness is ongoing value erosion: equity has declined materially from ~A$27.1m (2021) to ~A$13.9m (2025), and return on equity is consistently negative, reflecting continued losses and potential future funding needs if cash burn persists.

Cash Flow

Cash generation remains negative, with operating cash flow and free cash flow consistently below zero (2025 operating cash flow about -A$3.7m; free cash flow about -A$4.1m). Free cash flow worsened in 2025 versus 2024 (down ~24%), pointing to rising cash burn. A partial positive is that free cash flow tracks net losses closely (free cash flow to net income near ~1.0–1.1), suggesting losses are not being heavily distorted by non-cash items, but the overall cash runway risk remains elevated.

Breakdown	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	2.63M	152.24K	3.08K	171.92K	152.64K
Gross Profit	2.63M	150.51K	428.00	170.21K	152.64K
EBITDA	-4.72M	-6.51M	-5.14M	-7.01M	-189.44K
Net Income	-4.24M	-4.14M	-4.17M	-6.84M	-915.23K
Balance Sheet
Total Assets	14.57M	19.39M	22.38M	25.90M	27.61M
Cash, Cash Equivalents and Short-Term Investments	12.32M	16.44M	21.40M	25.46M	27.11M
Total Debt	0.00	0.00	0.00	0.00	7.50M
Total Liabilities	662.53K	1.35M	497.35K	559.64K	536.00K
Stockholders Equity	13.91M	18.04M	21.88M	25.34M	27.07M
Cash Flow
Free Cash Flow	-4.12M	-4.95M	-4.26M	-3.97M	-852.89K
Operating Cash Flow	-3.70M	-4.95M	-4.26M	-3.97M	-852.89K
Investing Cash Flow	-421.67K	-3.35K	-2.24K	-3.92K	5.00K
Financing Cash Flow	0.00	0.00	0.00	21.36M	7.46M

Tissue Repair Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRP, the sentiment is Negative. The current price of 0.38 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.28, and above the 200-day MA of 0.27, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 35.77 is Neutral, neither overbought nor oversold. The STOCH value of 42.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:TRP.

Tissue Repair Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PTX	50 Neutral	AU$69.40M	-6.60	-49.72%	―	―	10.78%
CMB	48 Neutral	AU$11.25M	-2.68	-166.70%	―	―	―
AVE	48 Neutral	AU$36.73M	-7.14	-143.71%	―	306.88%	―
BGT	46 Neutral	AU$10.07M	-3.47	―	―	―	―
TRP	45 Neutral	AU$9.67M	-2.51	-26.53%	―	178.06%	-2.49%
1AD	37 Underperform	AU$10.20M	-2.38	-628.72%	―	―	31.87%

Tissue Repair Ltd Corporate Events

Tissue Repair Issues 175,000 Unquoted Options Under Employee Incentive Plan

Tissue Repair Ltd has issued a total of 175,000 unquoted options under its employee incentive scheme, split between 75,000 options exercisable at $1.15 expiring in March 2039 and 100,000 options exercisable at $0.75 expiring in April 2041. These options are subject to transfer restrictions and will not be quoted on the ASX until those restrictions lapse, indicating an ongoing strategy to incentivise key staff while limiting immediate dilution in the market.

The move underscores Tissue Repair’s continued use of long-dated equity incentives to support retention and alignment of employees with long-term performance goals. For existing shareholders, the announcement signals a controlled approach to future potential dilution tied to staff participation, rather than a broad capital raise or immediate expansion of the quoted securities on issue.

The most recent analyst rating on (AU:TRP) stock is a Hold with a A$0.16 price target. To see the full list of analyst forecasts on Tissue Repair Ltd stock, see the AU:TRP Stock Forecast page.

Tissue Repair Narrows Half-Year Loss as Revenue Jumps but Asset Base Thins

Tissue Repair Ltd reported a 54.5% increase in revenue to $305,820 for the half-year ended 31 December 2025, while narrowing its loss after tax by 15.1% to $2.17 million compared with the prior corresponding period. The company did not declare any dividends, and net tangible assets per share declined from 25.77 cents to 19.57 cents, indicating ongoing investment and cash burn as it progresses its operations, with its half-year financial statements reviewed by auditors without noted disputes.

The results underscore a business that is still loss-making but showing improving revenue traction and reduced losses, which may reassure investors about operational momentum despite balance sheet dilution. The absence of dividends and the fall in net tangible assets per share highlight that shareholders remain reliant on future growth and commercialisation milestones for value, rather than near-term cash returns.

The most recent analyst rating on (AU:TRP) stock is a Hold with a A$0.16 price target. To see the full list of analyst forecasts on Tissue Repair Ltd stock, see the AU:TRP Stock Forecast page.

Tissue Repair Balances Slower TR987 Trial with Aggressive TR Pro+ Commercial Push

Tissue Repair reported slower patient randomisation in its US Phase 3 trial of TR987 for chronic wounds, with about 40 patients enrolled so far and a goal of 100 by July 2026 to trigger an interim analysis that will determine whether the late-stage program continues. The company also confirmed the FDA will classify TR987 as a drug rather than a biologic, while signalling that if interim trial goals are not met it will curtail the Phase 3 program and pivot more aggressively to commercialising its TR Pro+ wound care product line. In parallel, Tissue Repair is ramping up TR Pro+ distribution via a partnership with Advanced Cosmeceuticals in Australia, expecting a sales uplift once a full range of SKUs becomes available in March 2026, and pursuing regulatory approvals, including 510(k) and CE marks, to support global market entry. The company is expanding its Glucoprime-powered wound and skin care portfolio, securing new distribution in Thailand, and progressing discussions with partners in the US, EU and Southeast Asia, while managing quarterly cash outflows driven by R&D and manufacturing costs with a cash balance of $8.229 million at 31 December 2025.

The most recent analyst rating on (AU:TRP) stock is a Hold with a A$0.30 price target. To see the full list of analyst forecasts on Tissue Repair Ltd stock, see the AU:TRP Stock Forecast page.

Tissue Repair Limited Addresses ASX Price Query

Tissue Repair Limited has responded to an ASX price query, confirming that it is not aware of any undisclosed information that could explain recent trading activity in its securities. The company asserts compliance with listing rules and confirms that its responses have been authorized under its continuous disclosure policy.

Tissue Repair Ltd Announces Director’s Acquisition of Unlisted Options

Tissue Repair Ltd has announced a change in the director’s interest, specifically involving Patryk Kania, who has acquired 261,000 unlisted options. These options are exercisable at $1.15 and will expire on 26 November 2040, following approval at the company’s Annual General Meeting. This change reflects a strategic move in the company’s governance and could potentially impact its market operations by aligning director interests with long-term company performance.